$3.15 +0.33 (10.48%)

Metagenomi, Inc. Common Stock (MGX)

Metagenomi, Inc. (MGX) is a biotechnology company focused on the development of next-generation gene editing therapies. Leveraging its proprietary platform, the company aims to create precise, safe, and effective genetic treatment solutions for a range of genetic diseases and conditions.

🚫 Metagenomi, Inc. Common Stock does not pay dividends

Company News

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
GlobeNewswire Inc. • N/A • May 14, 2025

Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.

Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps
Seeking Alpha • Wall Street Week Ahead • March 2, 2024

Stay informed of upcoming IPOs, earnings reports, and market events with Seeking Alpha's Stocks to Watch newsletter.

This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
The Motley Fool • [email protected] (Alex Carchidi) • February 19, 2024

A bumpy start can't detract from this company's strong balance sheet.

Related Companies